by These drugs help reduce body weight by decreasing appetite or increasing feelings of fullness. The market landscape comprises appetite suppressants, lipase inhibitors, serotonin-based drugs, combinations of above and many others.
The Global Anti-Obesity Drug Market is estimated to be valued at US$ 2928.39 Mn in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024 to 2031.
Obesity has emerged as a major public health crisis in both developing and developed nations. Anti-obesity drugs play a vital role in facilitating long-term weight management along with lifestyle changes such as diet and exercise. They target various pathways that control food intake and energy expenditure. The effectiveness of these drugs in achieving modest and sustained weight loss makes them an attractive treatment option. Additionally, they reduce obesity-related comorbidities like hypertension, cardiovascular diseases and diabetes.
Key Takeaways
Key players operating in the anti-obesity drug market are ARJO, Etac AB, Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation, Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation, Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria Corporation (Handicare Group AB), among others.
The growing prevalence of obesity due to poor eating habits and sedentary lifestyles is fueling the demand for Anti-Obesity Drugs Market Size globally. As per estimates, around 650 million adults and 120 million children are obese worldwide. Anti-obesity medications are increasingly being prescribed as an adjunct to diet and exercise therapy.
Major pharmaceutical companies are expanding their geographic footprints in developing markets like Asia Pacific and Latin America that are experiencing rising obesity rates. This is attributed to growing health awareness, increasing discretionary incomes and rising focus of companies on emerging economies.
Market Key Trends
Rising penetration of digital health technologies is a key trend gaining traction in the anti-obesity drug market. Technologies like connected wearables, mobile apps, telehealth platforms and virtual care services are being utilized to remotely monitor patients, enhance medication adherence and provide on-demand health coaching/support. They enable continuous care and improve treatment outcomes in a cost-effective manner. This supports the increasing adoption of anti-obesity therapeutics globally.
Porter’s Analysis
Threat of new entrants: High costs of R&D, clinical trials, and regulatory approvals pose barriers for new companies.
Bargaining power of buyers: Individual consumers have low bargaining power whereas large retailers and institutions can negotiate for lower prices.
Bargaining power of suppliers: Companies depend on few suppliers for specialized raw materials increasing supplier bargaining power.
Threat of new substitutes: Alternative therapies such as bariatric surgery and healthy lifestyle changes pose threats.
Competitive rivalry: Intense completion between large pharmaceutical companies to develop new and more effective anti-obesity drugs.
The North American region dominates the global anti-obesity drug market held over 40% revenue share in 2024 owing to high obesity rates, high healthcare expenditure, and favorable reimbursement policies.The Asia Pacific region is expected to be the fastest growing market during the forecast period due to rising disposable income, growing awareness regarding obesity, increasing healthcare spending in developing countries such as China and India.
Geographical Regions
North America held the largest share of the global anti-obesity drug market in 2024 and is expected to continue dominating during the forecast period. This is attributed to increasing prevalence of obesity due to sedentary lifestyle and unhealthy eating habits. Additionally, high healthcare spending and presence of major market players in the US and Canada boost market growth.
The Asia Pacific region is projected to witness the fastest growth during 2024 to 2031. Rapid economic development, rising living standards, growing medical tourism industry and increasing government initiatives to spread awareness about obesity are driving market growth. China and India have emerged as profitable markets due to rising healthcare expenditure, large patient pools and presence of generic manufacturers.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
